Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma - Aix-Marseille Université Access content directly
Journal Articles European Journal of Cancer Year : 2018

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

Marco Fornili
Gert van den Eynden
  • Function : Author
Françoise Rothé
  • Function : Author
Laurence Buisseret
  • Function : Author
Karen Willard-Gallo
David Brown
Ian Ellis
  • Function : Author
Emad Rakha
  • Function : Author
Denis Larsimont
  • Function : Author
Elia Biganzoli
Christos Sotiriou
Olivier Mir
Antoine Italiano
Jean-Yves Blay
Wolfgang Eisterer
  • Function : Author
Bernadette Liegl-Antzwager
  • Function : Author
Julien Thery
  • Function : Author
Axel Le Cesne
  • Function : Author
Marie-Cécile Le Deley
  • Function : Author

Domains

Cancer
No file

Dates and versions

hal-03623702 , version 1 (29-03-2022)

Identifiers

Cite

Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert van den Eynden, et al.. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer, 2018, 99 (7), pp.28-36. ⟨10.1016/j.ejca.2018.05.008⟩. ⟨hal-03623702⟩
33 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More